Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2019.01.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" aims to provide updated recommendations for clinicians treating atrial fibrillation patients.
- A thorough literature review was conducted to gather evidence from various medical databases, including studies and reviews published on human subjects from May to November 2022.
- The guideline updates previous recommendations, introducing new strategies for thromboembolic risk assessment, anticoagulation, and methods for prevention and management of atrial fibrillation.
Article Synopsis
- The 2023 guideline aims to provide healthcare professionals with updated recommendations for diagnosing and managing patients with atrial fibrillation.
- A thorough literature review was conducted to gather relevant studies and evidence from multiple databases, ensuring the guideline reflects current knowledge and practices.
- The guidelines build upon earlier recommendations, introducing new insights on thromboembolic risk, anticoagulation, surgical options, and preventive measures related to atrial fibrillation.
A large-scale multi-label 12-lead electrocardiogram database with standardized diagnostic statements.
Sci Data
June 2022
Shandong Artificial Intelligence Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
Deep learning approaches have exhibited a great ability on automatic interpretation of the electrocardiogram (ECG). However, large-scale public 12-lead ECG data are still limited, and the diagnostic labels are not uniform, which increases the semantic gap between clinical practice. In this study, we present a large-scale multi-label 12-lead ECG database with standardized diagnostic statements.
View Article and Find Full Text PDFManagement of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines.
Can J Cardiol
October 2021
University of British Columbia, Vancouver, British Columbia, Canada; Montréal Heart Institute, Université de Montréal, Montréal, Québec, Canada; Center for Cardiovascular Innovation, Vancouver, British Columbia, Canada. Electronic address:
Given its complexity, the management of atrial fibrillation (AF) has relied increasingly on expert guideline recommendations; however, discrepancies between these professional societies can lead to confusion among practicing clinicians. This article compares the recommendations in the 2019 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS), the 2020 European Society of Cardiology (ESC), and the 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society (CCS/CHRS) AF guidelines. Although many of the recommendations are fundamentally similar, there are important differences among guidelines; specifically, key differences are present in (1) definitions and classification of AF; (2) the role of opportunistic AF detection; (3) symptom and quality-of-life evaluation; (4) stroke-risk stratification and the indication for oral anticoagulation (OAC) therapy; (5) the role of aspirin in prevention of stroke for patients with AF; (6) the antithrombotic regimens employed in the context of coronary artery disease; (7) the role of OAC, and specifically non-vitamin K direct-acting oral anticoagulants (DOACs), in patients with chronic and end-stage renal disease; (8) the target heart rate for patients treated with a rate-control strategy, along with the medications recommended to achieve the heart-rate target; and (9) the role of catheter ablation as first-line therapy or in patients with heart failure.
View Article and Find Full Text PDFAdherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.
Int J Vasc Med
April 2021
Cardiology Department, Aqaba Isl Hospital, 15 Sharif Shaker Ben Zaidstreet, Aqaba 77110, Jordan.
Background: There is a scarcity of studies that evaluate adherence to the utilization of guideline-recommended oral anticoagulant agents (OACs) in patients with atrial fibrillation (AF) in the Middle East. The Jordan Atrial Fibrillation (JoFib) Study evaluated baseline clinical profiles and the utilization of OACs, including vitamin K antagonists (VKAs) and direct OACs (DOACs), in patients with valvular AF (VAF) and nonvalvular AF (NVAF) according to the 2019 focused update of the 2014 AHA/ACC/HRS guidelines.
Methods: Consecutive patients with AF were enrolled in 29 hospitals and outpatient clinics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!